{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:44:32Z","timestamp":1790066672713,"version":"4.0.1"},"reference-count":21,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:p>End points that provide an early identification of treatment effects are needed to implement type 1 diabetes prevention trials more efficiently. To this end, we assessed whether metabolic end points can be used to detect a teplizumab effect on rapid \u03b2-cell decline within 3 months after treatment in high-risk individuals in the TrialNet teplizumab trial. Glucose and C-peptide response curves (GCRCs) were constructed by plotting mean glucose and C-peptide values from 2-h oral glucose tolerance tests on a two-dimensional grid. Groups were compared visually for changes in GCRC shape and movement. GCRC changes reflected marked metabolic deterioration in the placebo group within 3 months of randomization. By 6 months, GCRCs resembled typical GCRCs at diagnosis. In contrast, GCRC changes in the teplizumab group suggested metabolic improvement. Quantitative comparisons, including two novel metabolic end points that indicate GCRC changes, the within-quadrant end point and the ordinal directional end point, were consistent with visual impressions of an appreciable treatment effect at the 3- and 6-month time points. In conclusion, an analytic approach combining visual evidence with novel end points demonstrated that teplizumab delays rapid metabolic decline and improves the metabolic state within 3 months after treatment; this effect extends for at least 6 months.<\/jats:p>","DOI":"10.2337\/db21-0519","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T17:10:14Z","timestamp":1632330614000},"page":"2922-2931","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":19,"title":["The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes"],"prefix":"10.2337","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct01030861","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-954X","authenticated-orcid":false,"given":"Emily K.","family":"Sims","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatrics Epidemiology Center, Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan C.","family":"Herold","sequence":"additional","affiliation":[{"name":"Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7204-8367","authenticated-orcid":false,"given":"Jay M.","family":"Sosenko","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"2022031310172502300_B1","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"2022031310172502300_B2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031310172502300_B3","doi-asserted-by":"crossref","first-page":"eabc880","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"2022031310172502300_B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","article-title":"C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001","volume":"53","author":"Palmer","year":"2004","journal-title":"Diabetes"},{"key":"2022031310172502300_B5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2337\/dc07-1459","article-title":"A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1","volume":"31","author":"Sosenko","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B6","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2337\/dc11-0641","article-title":"Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study","volume":"34","author":"Sosenko","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B7","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/dc12-0011","article-title":"The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes","volume":"35","author":"Sosenko","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B8","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2337\/dc17-0916","article-title":"Dysglycemia and Index60 as prediagnostic end points for type 1 diabetes prevention trials","volume":"40","author":"Nathan","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2337\/dc14-1813","article-title":"A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history","volume":"38","author":"Sosenko","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2337\/dc13-2359","article-title":"Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes","volume":"37","author":"Sosenko","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2337\/db09-1378","article-title":"Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset","volume":"59","author":"Ferrannini","year":"2010","journal-title":"Diabetes"},{"key":"2022031310172502300_B12","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.2337\/dc20-0701","article-title":"The pathological evolution of glucose response curves during the progression to type 1 diabetes in the TrialNet Pathway to Prevention Study","volume":"43","author":"Ismail","year":"2020","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00125-020-05365-4","article-title":"Index60 as an additional diagnostic criterion for type 1 diabetes","volume":"64","author":"Redondo","year":"2021","journal-title":"Diabetologia"},{"key":"2022031310172502300_B14","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2337\/db20-0166","article-title":"Slowed metabolic decline after 1 year of oral insulin treatment among individuals at high risk for type 1 diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials","volume":"69","author":"Sosenko","year":"2020","journal-title":"Diabetes"},{"key":"2022031310172502300_B15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2337\/db20-0817","article-title":"Baseline assessment of circulating microRNAs near diagnosis of type 1 diabetes predicts future stimulated insulin secretion","volume":"70","author":"Snowhite","year":"2021","journal-title":"Diabetes"},{"key":"2022031310172502300_B16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2337\/diacare.18.2.245","article-title":"The use of areas under curves in diabetes research","volume":"18","author":"Allison","year":"1995","journal-title":"Diabetes Care"},{"key":"2022031310172502300_B17","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"2022031310172502300_B18","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031310172502300_B19","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031310172502300_B20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"key":"2022031310172502300_B21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/70\/12\/2922\/634616\/db210519.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/70\/12\/2922\/634616\/db210519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:42:58Z","timestamp":1667407378000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/70\/12\/2922\/139068\/The-Deterrence-of-Rapid-Metabolic-Decline-Within-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,22]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db21-0519","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}